Alpha-1 genetic and blood testing for people at risk
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study checks whether doing alpha-1 screening (genetic test and a blood level test) can help identify alpha-1 antitrypsin deficiency in people at risk. It may be useful if you have symptoms or a family history, but you haven’t had qualifying testing yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You may be any age, as long as you’re at risk for alpha-1 antitrypsin deficiency
- You’re considered “at risk” based on symptoms you have
- You can also qualify if you have a family history of alpha-1
- You must not have already completed both genotype testing and a blood AAT level test with a “qualified result”
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a DNA and tissue sample registry for people interested in Alpha-1. It helps researchers study the condition by collecting samples for future research.
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
This study looks at how lung disease changes a type of blood cell called white blood cells. It may help researchers understand what’s happening in the lungs and how to better monitor or treat lung problems.
This study collects health information from people who have alpha-1 antitrypsin deficiency. It may help doctors better understand the condition and improve care over time.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
This registry study enrolls people with Alpha-1 Antitrypsin Deficiency or certain genetic “carriers” to help researchers learn more about the condition. If you join, you may be asked to share health information over time.
Hear when a new Alpha 1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.